Press Releases

Switch to mobile view »
5/20/2008
Mission Pharmacal Launches Ferralet® 90 for Treatment of the Leading Cause of Anemia in the U.S. Designed to improve on existing oral iron therapies Full Release»
12/5/2007
Mission Pharmacal Sells Gold Standard Kidney Stone Diagnostic Tests to Quest Diagnostics Full Release»
8/30/2007
Mission Pharmacal Sells Citracal® Calcium Brand to Bayer HealthCare Plans Exciting Future as Specialty Pharmaceutical Company Full Release»
7/31/2007
New Study Finds Tindamax® To Be Effective, Well-Tolerated Treatment for Bacterial Vaginosis Full Release»
5/24/2007
FDA Approves Tindamax® for Bacterial Vaginosis First New Oral Treatment for Bacterial Vaginosis in a Decade Full Release»
11/13/2006
Centers for Disease Control and Prevention Recommends Tindamax® for the Treatment of Trichomoniasis in Latest Sexually Transmitted Disease Guidelines Full Release»
8/17/2006
Mission Pharmacal Submits Supplemental New Drug Application for Tindamax® (Tinidazole) as Treatment of Bacterial Vaginosis Full Release»
5/9/2006
Most Common Curable STD a Significant Public Health Concern When Untreated, May Contribute to Spread of HIV New Web Resource Launched to Educate on Trichomoniasis Treatment Full Release»
5/8/2006
Mission Pharmacal Completes Phase III Study of Tindamax® for the Treatment of Bacterial Vaginosis Full Release»
4/20/2006
Mission Pharmacal Acquires Tindamax®: Treatment for Trichomoniasis, Most Common Non-Viral Sexually Transmitted Disease Potent, Well-Tolerated Therapy Allows Simple One-Day, One-Dose Regimen Full Release»